Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of a Single Intraoperative Localized Instillation of 4975 in Patients Undergoing Primary Unilateral Total Hip Arthroplasty
Sponsor: Anesiva, Inc.
Terminated
Enrollment of patients has halted prematurely and will not resume. No future patients will be enrolled or treated.
Other terminated trials from Anesiva, Inc.
- Intravenous Placement Procedure · Apr 2009
- Rotator Cuff Repair of the Shoulder · Phase PHASE2 · Dec 2008
- Chronic Renal Failure · Phase PHASE1/PHASE2
More terminations from Anesiva, Inc.
Other Arthroplasty trials with similar outcome
Listed as NCT00683267, this PHASE2 trial focuses on Arthroplasty and remains terminated or withdrawn. Sponsored by Anesiva, Inc., it has been updated 10 times since 2007, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Sep 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Anesiva, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .